A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe cGVHD after transplant in people who received nonmyel...

Bone Marrow Transplantation - Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the...

Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic haematopoietic cell transplantation. cGVHD has a heterogeneous biology and morbid manifestations, affecting 30–70% of recipients and substantially impairing quality of life and is the leading cause of non-relapse mortality in allo-HCT recipients. This immune-mediated condition arises from complex immune dysregulation involving B cell and T cell activation, regulatory T cell dysfunction, and fibrosis driven by macrophages and fibroblasts. Glucocorticoids remain the first-line treatment; however, ~50% of patients develop steroid-refractory or steroid-dependent cGVHD, necessitating prolonged immunosuppression causing considerable toxicity. Four second-line treatments have been approved by the FDA — ibrutinib, ruxolitinib, belumosudil and axatilimab — targeting B cell signalling, JAK–STAT, ROCK2 and CSF1R pathways, respectively, and emerging therapies such as rovadicitinib show promise. However, substantia

Key PointsConcept elicitation demonstrates symptoms and functions of cGVHD-associated sclerosis not captured by existing outcome measures.The Lee Symptom S

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.